首页|人β干扰素与人血清白蛋白融合蛋白的表达及纯化

人β干扰素与人血清白蛋白融合蛋白的表达及纯化

扫码查看
为开展人β干扰素-人血清白蛋白融合蛋白(IFNβ-HAS)的临床前研究,本研究采用免疫学方法对毕赤酵母转化子进行筛选,得到高产菌株8株.在5 L发酵罐上对高产菌株进行诱导表达,产量达500 mg/L.发酵液经超滤浓缩、染料亲和层析、镍离子螯合亲和层析和DEAE离子交换层析纯化后.融合蛋白纯度达到96%.Western blotting杂交表明融合蛋白具有人血清白蛋白和人β干扰素的抗原性,细胞病变抑制法测定IFNβ-HSA比活性为1.96 × 10~7IU/mg.建立了融合蛋白的生产工艺,为IFNβ-HSA的临床前研究奠定了基础.
Expression and purification of IFNβ-HAS fusion protein in Pichia pastoris
In order to obtain enough fusion protein for developing preclinieal studies of IFNβ-HAS, we screened Pichia pastoris transformants expressing high-level protein by immunology method.The yield of IFNβ-HSA was about 500 mg/L by fed-batch fermentation.The purity of IFNβ-HSA reached 96% through the steps of ultrafiltration, Blue Sepharose FF, Ni~(2+)-IMAC and DEAE Sepharose FE Analysis of Western blotting showed that IFNβ-HSA had the antigenicity of IFNβ and HSA.The specific activity was about 1.96×10~7 IU/mg by standard survival activity test on WISH cells challenged with VSV virus.This study provided a method to produce IFNβ-HSA.

IFNβfusion proteinPichiapastoris

张琦、雷楗勇、丁月娣、陈蕴、屈琳、陈淑娴、金坚

展开 >

江南大学医药学院细胞与分子药理学实验室,无锡,214122

β干扰素 融合蛋白 毕赤酵母

国家高技术研究发展计划(863计划)

2006AA02Z153

2009

生物工程学报
中国科学院微生物研究所 中国微生物学会

生物工程学报

CSTPCDCSCD北大核心
影响因子:0.641
ISSN:1000-3061
年,卷(期):2009.25(11)
  • 6
  • 6